Provisional Results Announced for Provincial Alliance Centralized Procurement of Two Categories of Medical Consumables: Multinational and Domestic Enterprises Included

# Pacemaker Centralized Procurement Results Announced, International Companies Still Dominate

According to the public announcement results, inImplantable Cardiac Pacemaker ProductsIn China, multiple international manufacturers have made it to the list of tentative winners.

Mainly include:

• BIOTRONIK
• Medtronic
• Abbott (Abbott / St. Jude Medical)

Related products involve:

• Implantable Single-Chamber Cardiac Pacemaker
• Implantable Dual-Chamber Cardiac Pacemaker
• Cardiac Resynchronization Therapy Pacemaker (CRT-P)
• Pacemaker electrode leads and other配套耗材

Cardiac pacemakers are important implantable devices for the treatment of arrhythmias. Based on different indications, common clinical products includeSingle-chamber, dual-chamber, and CRT pacing systems。

For a long time, this field has had high technical barriers, with core manufacturers mainly concentrated in a few international enterprises. Although Chinese manufacturers have made progress in some supporting consumables and technical aspects, the overall market pattern remains relatively concentrated.

From the list of proposed winners this time,International leading enterprises continue to maintain strong competitivenessIn terms of clinical usage habits, product stability, and long-term follow-up data, these companies still have obvious advantages.

However, with the continuous advancement of centralized procurement, the price system for pacemaker products is also gradually being adjusted. The industry generally believes that as policies become more deeply implemented, future breakthroughs by Chinese manufacturers in certain niche products are still worth paying attention to.

# Microcatheters Included in Centralized Procurement, Participation of Chinese Enterprises Significantly Increases

Unlike pacemakers, another category of products in this round of centralized procurement——Interventional Microcatheter, showing a more pronounced trend of participation by domestically produced enterprises.

According to the procurement documents, this round of centralized procurement will divide microcatheters into two categories:

• Neurointerventional Microcatheter
• Peripheral Vascular Intervention Microcatheter

Both types of products belong to interventional therapy.Basic Pathway Devices, mainly used for delivering guidewires, coils, or other therapeutic devices in complex vascular pathways.

With the continuous growth in the volume of interventional procedures, the microcatheter market has maintained steady expansion in recent years.

# Neurointerventional Microcatheter

In the field of neurointerventional therapy, microcatheters are mainly used for:

• Coil Embolization of Cerebral Aneurysms
• Vascular Reconstruction
• Other Neurovascular Interventional Treatments

The proposed winning enterprises this time include both international manufacturers and multiple domestic companies.

International enterprises include:

• MicroVention
• Stryker Neurovascular

Domestic companies include:

• Beijing Taijie Weiye Technology Co., Ltd.
• Beijing Microfairy Medical Technology Co., Ltd.
• Jiangsu Changyida Medical Device Co., Ltd.
• Quantum Medical Technology (Suzhou) Co., Ltd.
• Jiangsu Nico Medical Device Co., Ltd., etc.

Neurointervention has maintained rapid growth in China in recent years. With the advancement of stroke prevention and treatment systems, the volume of neurointerventional surgeries continues to increase, leading to a growing demand for related consumables.

Against this backdrop, basic devices such as microcatheters have become one of the key areas of focus for domestically produced enterprises.

# Peripheral Vascular Intervention Microcatheter

InPeripheral Vascular Intervention MicrocatheterCategory, this round of centralized procurement is carried out according toDistal Outer Diameter SpecificationGroup bidding, for example:

• 2.0F < Distal Outer Diameter ≤ 3.0F
• 3.0F < Distal Outer Diameter ≤ 4.0F

The proposed winning enterprises include:

• Shenzhen Shunmei Medical
• Shenzhen Betterway Medical
• Dalian Curite Medical

Peripheral vascular interventional microcatheters are widely used in:

• Interventional Treatment of Peripheral Vascular Diseases
• Tumor Embolization Therapy
• Complex Vascular Pathway Delivery

Due to the relatively standardized product structure and lower technical barriers compared to some high-value implantable devices, domestic companies have accumulated a significant number of product layouts in this field in recent years.

# Enterprises with Low Price Quotes Need to Submit Cost Explanations

In this announcement, the regulatory authorities also put forward clear requirements for some low-price bidding situations.

According to the announcement, forEnterprises in the neurointervention microcatheter bidding unit with quotes lower than the "A bidding unit anchor price", the "Declaration of Quotation Rationality" must be submitted within the public notice period, explaining the product cost structure.

Relevant companies include:

• Quantum Medical (Suzhou)
• Jiangsu ChangYiDa Medical
• Jiangsu Nico Medical Device Co., Ltd.

If the company fails to submit the relevant materials within the specified time, it willDisqualification and Inclusion in the Violation List。

This mechanism reflects that, while pushing for price reductions, regulatory authorities are also strengthening their oversight.Abnormally Low Price QuoteThe review is to prevent vicious price competition.

# The Coverage of Basic Consumables for Interventional Procedures in China Continues to Expand

In recent years, the centralized bulk procurement of high-value medical consumables has been continuously advanced.

Previously, multiple cardiovascular-related fields have been successively included in centralized procurement, such as:

• Coronary Stent
• Pacemaker
• Heart Valve
• Peripheral vascular stents, etc.

And microcatheters, etc.Basic Interventional DevicesAlthough the unit price is relatively low, the high frequency of clinical use and stable market size have gradually made it an object of attention for centralized procurement policies.

With the publication of the results of this round of provincial alliance procurement,The policy coverage for consumables related to interventional treatments has been further expanded.。

In the industry's view, future centralized procurement may continue to move towardsMore Basic Interventional DevicesExtend, while finding a new balance between price control and market competition.

After the public announcement period ends, this round of centralized procurementThe final selection results are expected to be announced soon.。